Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.

"We believe the data from this study will demonstrate that the combination of MC4R + GLP-1/GIP agonists may ... medical need for alternative mechanisms of action that can provide physicians ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Ozempic is traditionally used as a treatment for type 2 diabetes (T2DM) to help patients manage blood sugar levels. However, ...

GLP1RA mimic the GLP-1 hormone in the body that helps control insulin and blood glucose levels and promotes feelings of satiety. GLP-1 binds to GLP1R on cells in the brain and pancreas.

Sitagliptin selectively inhibits the action of DPP-4 ... decline in ß-cell secretion. [1] In the presence of elevated glucose concentrations, GLP-1 and GIP increase insulin release and GLP ...